Einloggen
E-Mail
Passwort
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Idorsia Ltd
  6. News
  7. Übersicht
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen

GlobeNewswire/European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

25.05.2021 | 07:00
   Allschwil, Switzerland -- May 25, 2021 
 
   Idorsia Ltd (SIX: IDIA) was informed by the Janssen Pharmaceutical 
Companies of Johnson & Johnson that the European Commission (EC) has 
approved Ponvory(TM) (ponesimod) for the treatment of adult patients 
with relapsing forms of multiple sclerosis (RMS) with active disease 
defined by clinical or imaging features. 
 
   Idorsia and Actelion Pharmaceuticals Ltd, one of the Janssen 
Pharmaceutical Companies of Johnson & Johnson, have entered into a 
revenue-sharing agreement in respect to ponesimod. Under the terms of 
the revenue-sharing agreement, Idorsia is entitled to receive quarterly 
payments of 8% of the net sales of ponesimod products from Actelion. 
 
   For further details please read the full announcement from Janssen 
available he 
https://www.jnj.com/european-commission-approves-ponvorytm-ponesimod-a-once-daily-oral-therapy-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis-with-active-disease-defined-by-clinical-or-imaging-features 
r 
https://www.jnj.com/european-commission-approves-ponvorytm-ponesimod-a-once-daily-oral-therapy-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis-with-active-disease-defined-by-clinical-or-imaging-features 
e 
https://www.jnj.com/european-commission-approves-ponvorytm-ponesimod-a-once-daily-oral-therapy-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis-with-active-disease-defined-by-clinical-or-imaging-features 
. 
 
   Notes to the editor 
 
   Adverse events should be reported. This medicinal product is subject to 
additional monitoring and it is therefore important to report any 
suspected adverse events related to this medicinal product. 
 
   About Idorsia 
 
   Idorsia Ltd is reaching out for more -- We have more ideas, we see more 
opportunities and we want to help more patients. In order to achieve 
this, we will develop Idorsia into a leading biopharmaceutical company, 
with a strong scientific core. 
 
   Headquartered near Basel, Switzerland -- a European biotech-hub -- 
Idorsia is specialized in the discovery, development and 
commercialization of small molecules to transform the horizon of 
therapeutic options. Idorsia has a broad portfolio of innovative drugs 
in the pipeline, an experienced team of professionals covering all 
disciplines from bench to bedside, state-of-the-art facilities, and a 
strong balance sheet -- the ideal constellation to translate R&D efforts 
into business success. 
 
   Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in 
June 2017 and has over 900 highly qualified specialists dedicated to 
realizing our ambitious targets. 
 
   For further information, please contact 
 
   Andrew C. Weiss 
 
   Senior Vice President, Head of Investor Relations & Corporate 
Communications 
 
   Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil 
 
   +41 58 844 10 10 
 
   investor.relations@idorsia.com 
 
   media.relations@idorsia.com 
 
   www.idorsia.com 
 
   The above information contains certain "forward-looking statements", 
relating to the company's business, which can be identified by the use 
of forward-looking terminology such as "estimates", "believes", 
"expects", "may", "are expected to", "will", "will continue", "should", 
"would be", "seeks", "pending" or "anticipates" or similar expressions, 
or by discussions of strategy, plans or intentions. Such statements 
include descriptions of the company's investment and research and 
development programs and anticipated expenditures in connection 
therewith, descriptions of new products expected to be introduced by the 
company and anticipated customer demand for such products and products 
in the company's existing portfolio. Such statements reflect the current 
views of the company with respect to future events and are subject to 
certain risks, uncertainties and assumptions. Many factors could cause 
the actual results, performance or achievements of the company to be 
materially different from any future results, performances or 
achievements that may be expressed or implied by such forward-looking 
statements. Should one or more of these risks or uncertainties 
materialize, or should underlying assumptions prove incorrect, actual 
results may vary materially from those described herein as anticipated, 
believed, estimated or expected. 
 
 
 
   Anhang 
 
 
   -- Medienmitteilung PDF 
      https://ml-eu.globenewswire.com/Resource/Download/e4fefcf4-4055-412a-bfb3-cc52fd94dbcf 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 25, 2021 01:00 ET (05:00 GMT)

Im Artikel erwähnte Wertpapiere
%Kurs01.01.
DJ INDUSTRIAL -0.36%34930.93 verzögerte Kurse.14.83%
IDORSIA LTD -10.16%22.1 verzögerte Kurse.-13.40%
Alle Nachrichten zu IDORSIA LTD
07:01GlobeNewswire/Application of Jean-Paul and -2-
DJ
07:01GlobeNewswire/Application of Jean-Paul and Martine Clozel regarding the exemp..
DJ
28.07.Idorsia gibt Wandelanleihe über 600 Millionen Franken aus
AW
28.07.GlobeNewswire/Idorsia announces the reference -2-
DJ
28.07.GlobeNewswire/Idorsia announces the reference share price and the initial con..
DJ
28.07.Aktien Schweiz Schluss: Moderate Gewinne vor Fed-Entscheid
AW
28.07.GlobeNewswire/Idorsia successfully completes the -2-
DJ
28.07.GlobeNewswire/Idorsia successfully completes the offering of convertible bond..
DJ
28.07.Aktien Schweiz: SMI freundliche Tendenz vor Fed - Adecco unter Druck
AW
28.07.Aktien Schweiz Eröffnung: SMI zieht vor Fed etwas an - Adecco unter Druck
AW
Weitere Nachrichten
News auf Englisch zu IDORSIA LTD
07:07IDORSIA : Application of Jean-Paul and Martine Clozel regarding the exemption fr..
PU
07:01PRESS RELEASE : Application of Jean-Paul and -2-
DJ
07:01PRESS RELEASE : Application of Jean-Paul and Martine Clozel regarding the exempt..
DJ
05:35IDORSIA : Places $660 Million Convertible Bonds Due 2028; Shares Down 10%
MT
28.07.IDORSIA : announces the reference share price and the initial conversion price o..
AQ
28.07.PRESS RELEASE : Idorsia announces the reference -2-
DJ
28.07.PRESS RELEASE : Idorsia announces the reference share price and the initial conv..
DJ
28.07.IDORSIA : successfully completes the offering of convertible bonds, securing fun..
PU
28.07.PRESS RELEASE : Idorsia successfully completes the -2-
DJ
28.07.PRESS RELEASE : Idorsia successfully completes the offering of convertible bonds..
DJ
Weitere Nachrichten auf Englisch
Finanzkennziffern
Umsatz 2021 31,5 Mio 34,6 Mio -
Nettoergebnis 2021 -638 Mio -701 Mio -
Nettoverschuldung 2021 378 Mio 415 Mio -
KGV 2021 -5,65x
Dividendenrendite 2021 -
Marktkapitalisierung 3 697 Mio 4 046 Mio -
Marktkap. / Umsatz 2021 129x
Marktkap. / Umsatz 2022 49,9x
Mitarbeiterzahl 650
Streubesitz 63,4%
Chart IDORSIA LTD
Dauer : Zeitraum :
Idorsia Ltd : Chartanalyse Idorsia Ltd | MarketScreener
Vollbild-Chart
Chartanalyse-Trends IDORSIA LTD
KurzfristigMittelfristigLangfristig
TrendsFallendFallendFallend
Ergebnisentwicklung
Analystenschätzung
Verkaufen
Kaufen
Durchschnittl. Empfehlung HALTEN
Anzahl Analysten 11
Letzter Schlusskurs 22,10 CHF
Mittleres Kursziel 29,73 CHF
Abstand / Durchschnittliches Kursziel 34,5%
Revisionen zum Gewinn je Aktie
Vorstände und Aufsichtsräte
Jean-Paul Clozel Chief Executive Officer & Director
André C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Branche und Wettbewerber
01.01.Wert (M$)
IDORSIA LTD-13.40%4 046
GILEAD SCIENCES, INC.20.25%86 451
BIONTECH SE284.51%68 592
WUXI APPTEC CO., LTD.36.10%64 659
REGENERON PHARMACEUTICALS21.38%60 167
VERTEX PHARMACEUTICALS-14.43%52 511